论文部分内容阅读
为了探索重组IL6-PE40融合蛋白靶向杀伤白血病的效应,我们已成功地将编码人IL6R的全长cDNA转入BNML大鼠急性早幼粒细胞白血病LT12细胞中。本文研究了IL6RcDNA转入LT12细胞后对该细胞原有生物学特性的影响。结果表明:①LT12-IL6R ̄+细胞与原代细胞五种酶学组化无任何区别;②LT12-IL6R ̄+细胞不仅高表达IL6R而且仍保持原有的表面抗原性质,如与RM-124单抗结合;③在白血病细胞体内外克隆源试验中,两种细胞系等同;④更重要的是LT12-IL6R ̄+细胞的致瘤特性无异于LT12原代细胞。证明LT12-IL6R ̄+仍为急性早幼粒细胞白血病。
To explore the effect of recombinant IL6-PE40 fusion targeting leukemia, we have successfully transferred the full-length cDNA encoding human IL6R into BNML rat acute promyelocytic leukemia LT12 cells. This article studies the IL6RcDNA into LT12 cells after the original biological characteristics of the cell. The results showed that: ①LT12-IL6R ~ + cells had no difference from the five kinds of enzymatic histochemistry of primary cells; ②LT12-IL6R ~ + cells not only highly expressed IL6R but also maintained the original surface antigenic properties, ; ③ In the in vitro and in vivo clonogenic assay of leukemia cells, the two cell lines are identical; ④ More importantly, the tumorigenic characteristics of LT12-IL6R ~ + cells are no different from those of LT12 primary cells. Proved that LT12-IL6R ~ + is still acute promyelocytic leukemia.